Our Services
Medical Information
Helpful Resources
Published on: 10/1/2026
Zofran (ondansetron) typically begins easing nausea within 30 minutes of an oral dose and within 5 to 15 minutes when given by IV, while the orally dissolving tablet works on a similar timeline to standard tablets. Its effects generally last about 4 to 8 hours, which is why dosing is often repeated every 8 hours, though timing varies by form, dose, age, liver function, and the cause of the nausea. There are several important factors and warning signs to consider, so see below to understand more before deciding whether to redose or seek care.
If relief is not coming when expected, or nausea keeps returning between doses, that pattern can point to an underlying cause that needs a different approach. A free, instant, online symptom check can help you organize what you are feeling, flag symptoms that deserve prompt attention, and clarify the right next step, whether that is monitoring at home or contacting a clinician.
Last reviewed for medical accuracy: 10/01/2026
Zofran (ondansetron) is a widely used medication to prevent and treat nausea and vomiting caused by chemotherapy, radiation therapy, surgery or other conditions. Knowing how quickly it starts to relieve symptoms and how long its effects last can help you plan doses and manage expectations.
Zofran belongs to a class of drugs called 5-HT₃ (serotonin) receptor antagonists. It blocks serotonin signals in the gut and brain that trigger the vomiting reflex. Key points:
“How long does Zofran take to work?” depends on the formulation:
Oral Tablets
Orally Disintegrating Tablets (ODT)
Intravenous (IV) Injection
Once Zofran starts working, its effects can last long enough to cover most high-risk periods for nausea:
Several factors may speed up or slow down how Zofran works:
Below are general dosing schedules—always follow your doctor or pharmacist’s instructions:
• For Chemotherapy-Induced Nausea
– Adults: 8 mg orally 30 minutes before chemotherapy, then every 8 hours for 1–2 days after.
– Children (4–11 years): 4 mg 30 minutes before therapy, repeat every 8 hours.
• For Postoperative Nausea
– Adults: 4 mg IV or oral at induction of anesthesia or post-op; may repeat once after 4 hours.
• For Radiation-Induced Nausea
– Adults: 8 mg orally 1–2 hours before radiation, then every 8 hours during treatment.
Zofran is generally well tolerated, but it can cause side effects. Most are mild:
Less common but more serious effects:
Tell your doctor about all medications and supplements you take to avoid interactions. If you have a history of heart rhythm issues, liver disease or severe dehydration, your doctor may adjust your dose or monitor you more closely.
Although most nausea improves with Zofran, some situations require prompt evaluation:
If you experience chest pain, fainting or irregular heartbeat, call emergency services immediately.
If you’re ever unsure whether your symptoms are cause for concern, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Understanding “Zofran how long to work” and its duration can help you manage nausea more effectively. By choosing the right formulation, following dosing instructions and watching for side effects, you can get the relief you need with minimal disruption.
Always discuss any new or worsening symptoms with your healthcare provider. For anything life-threatening or serious, speak to a doctor right away.
(References)
* Johnson BA, Rue J, Cowen PJ. Ondansetron and alcohol pharmacokinetics. Psychopharmacology (Berl). 1993;112(1):145. doi: 10.1007/BF02247376. PMID: 7871005.
* Copur MS, Ledakis P, Norvell M. Prevention of delayed emesis caused by chemotherapy. N Engl J Med. 2000 Sep 21;343(12):888-9; author reply 889-90. doi: 10.1056/NEJM200009213431213. PMID: 11001694.
* Harmon D, O'Brien B. Prevention of delayed emesis caused by chemotherapy. N Engl J Med. 2000 Sep 21;343(12):889; author reply 889-90. PMID: 11001695.
* Blower P, Aapro M. Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade? Br J Cancer. 2002 May 20;86(10):1662-3; author reply 1664. doi: 10.1038/sj.bjc.6600313. PMID: 12085221; PMCID: PMC2746584.
* Blum RA, Majumdar A, McCrea J, Busillo J, Orlowski LH, Panebianco D, Hesney M, Petty KJ, Goldberg MR, Murphy MG, Gottesdiener KM, Hustad CM, Lates C, Kraft WK, Van Buren S, Waldman SA, Greenberg HE. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther. 2003 May;25(5):1407-19. doi: 10.1016/s0149-2918(03)80128-5. PMID: 12867217.
* Gurjar MK. The future lies in chiral purity: a perspective. J Indian Med Assoc. 2007 Apr;105(4):177-8. PMID: 17822185.
* Zhang D, Mita M, Shapiro GI, Poon J, Small K, Tzontcheva A, Kantesaria B, Zhu Y, Bannerji R, Statkevich P. Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. Cancer Chemother Pharmacol. 2012 Dec;70(6):891-8. doi: 10.1007/s00280-012-1967-y. Epub 2012 Oct 9. PMID: 23053255.
* Peltz G, Anand KJ. Long-Acting Opioids for Treating Neonatal Abstinence Syndrome: A High Price for a Short Stay? JAMA. 2015 Nov 17;314(19):2023-4. doi: 10.1001/jama.2015.13537. PMID: 26469386; PMCID: PMC11938416.
* Huddart R, Altman RB, Klein TE. PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2019 Jun;29(4):91-97. doi: 10.1097/FPC.0000000000000369. PMID: 30672837; PMCID: PMC6476683.
* Ogasawara K, Vince B, Xu C, Zhang M, Palmisano M, Krishna G. A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects. Cancer Chemother Pharmacol. 2020 May;85(5):995-1001. doi: 10.1007/s00280-020-04074-4. Epub 2020 Apr 22. PMID: 32318809.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.